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Abstract 
Aim  Significant recent changes in management of locally advanced rectal cancer include 
preoperative staging, use of extended neoadjuvant therapies, and minimally invasive surgery (MIS). 
This study was aimed at characterizing those changes and associated short-term outcomes. 
Method  We retrospectively analyzed treatment and outcome data from patients with T3/4 or N+ 
locally advanced rectal cancer ≤15 cm from the anal verge who were evaluated at a comprehensive 
cancer center in 2009–2015. 
Results  In total, 798 patients were identified and grouped into five cohorts based on treatment year: 
2009-2010, 2011, 2012, 2013, and 2014-2015. Temporal changes included increased reliance on 
MRI staging, from 57% in 2009-2010 to 98% in 2014-2015 (p < 0.001); increased use of total 
neoadjuvant therapy, from 17% to 76% (p < 0.001); and increased use of MIS, from 33% to 70% (p 
< 0.001). Concurrently, median hospital stay decreased (from 7 to 5 days; p < 0.001), as did the rates 
of grade III-V complications (from 13% to 7%; p < 0.05), surgical site infections (from 24% to 8%; p 
< 0.001), anastomotic leak (from 11% to 3%; p < 0.05), and positive circumferential resection 
margin (from 9% to 4%; p < 0.05). TNM downstaging increased from 62% to 74% (p = 0.002). 
Conclusion  Shifts toward MRI-based staging, total neoadjuvant therapy, and MIS occurred between 
2009 and 2015. Over the same period, treatment responses improved, and lengths of stay and the 
incidence of complications decreased.   
 
 
What does this paper add to the literature? 
Shifts toward MRI-based staging, extended neoadjuvant therapy, and minimally invasive surgery for 
locally advanced rectal cancer have likely contributed to the observed improvements in the rates of 
downstaging, complications, and positive circumferential resection margins and in median hospital 
stay.  
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Introduction 
Clinical management of locally advanced rectal cancer (LARC) rapidly evolved over the past 30 
years, including improved staging; implementation of modern multimodality therapy consisting of 
chemotherapy, radiation, and surgery; and minimally invasive surgery (MIS).  The emergence of 
adjuvant chemoradiotherapy in the 1980s followed by adoption of neoadjuvant chemoradiotherapy 
(chemoRT), along with refinement in surgical technique, have markedly reduced local recurrence [1]. 
Improved staging with MRI has assisted in patient selection for neoadjuvant therapy and facilitated 
preoperative planning to achieve complete margin-negative resection [2, 3]. MIS and associated 
enhanced recovery programs have accelerated postoperative recovery and further reduced treatment-
related morbidity [4, 5].  
 
Currently, distant metastases remain the greatest risk for rectal cancer patients. Total neoadjuvant 
therapy (TNT) is aimed at early treatment of possible distant micrometastatic disease by delivering 
the full course of prescribed systemic chemotherapy in addition to standard chemoRT before surgery 
[6].  
 
In recent years, several of these major developments have been implemented into routine clinical 
practice shaping the management of LARC at many centers. It is not known whether these multiple 
modifications to LARC management, implemented over a relatively short period, act in synergy to 
improve short-term outcomes. Furthermore, the impact of extended neoadjuvant regimens on short-
term surgical outcomes is yet to be fully reported. With modern surgical treatments, including robotic 
assisted surgery, there also remains an ongoing need to prospectively evaluate surgical advances as a 
measure of progress and to justify such modifications in management. The aim of this study was to 
identify and detail modern trends in the surgical management of LARC at Memorial Sloan Kettering 
Cancer Center (MSK) between 2009 and 2015 (a period during which several potentially significant 
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changes in treatment practices had been implemented) and to evaluate associated short-term surgical 
and oncologic outcomes over this time.  
 
Method 
Patients  
MSK is a comprehensive cancer center with a high volume of rectal cancer patients. A waiver was 
obtained from the Institutional Review Board, and the MSK Colorectal Surgery Database was 
queried for patients presenting to the colorectal surgery clinic with LARC between June 1, 2009, and 
March 1, 2015 and considered for neoadjuvant therapy. This database provided basic demographics 
and treatment details, and a formal review of electronic medical records was conducted to collect 
additional data. We included patients with primary, nonmetastatic LARC confirmed as 
adenocarcinoma by pretreatment biopsy. LARC was defined in accordance with National 
Comprehensive Cancer Network (NCCN) guidelines based on staging with endorectal ultrasound 
(ERUS) or MRI as clinical (c)T3/T4 N0 or cN1/2 [7]. Staging computed tomography (CT) of the 
chest, abdomen, and pelvis with oral and intravenous contrast was performed prior to treatment. 
 
Patients were excluded if they had undergone previous surgery for metachronous rectal cancer, 
recurrent, or metastatic disease diagnosed at initial assessment or during neoadjuvant therapy or had 
complicated fistulizing anorectal inflammatory bowel disease. Patients with rectal cancer above 15 
cm from the anal verge or clinically above the peritoneal reflection were also excluded. 
 
Neoadjuvant and Adjuvant Therapy 
Neoadjuvant therapy was administered in accordance with the NCCN guidelines [7], which 
recommend it for disease of clinical stage T3, T4, or T-any N+. The majority of patients were treated 
according to the following planned neoadjuvant treatment paradigms: 1) chemoRT alone (or long- 
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course chemoRT), surgery, and adjuvant chemotherapy; 2) TNT followed by surgery; 3) systemic 
chemotherapy alone followed by surgery. In the TNT cohort, chemotherapy was delivered before 
chemoRT (referred to as induction chemotherapy) or after chemoRT (referred to as consolidation 
chemotherapy). Since delivery of both chemoRT and systemic chemotherapy occurs before surgery 
in the TNT paradigm, no postoperative therapy is required.   
 
Systemic chemotherapy generally consisted of capecitabine-oxaliplatin or folinic acid-fluorouracil-
oxaliplatin (FOLFOX) administered over 4 months.  Long-course chemoRT was delivered over 28 
standard fractions of radiotherapy with concurrent infusional fluorouracil or oral capecitabine.  
 
Assessment of Clinical Response  
Clinical office examination included digital examination and flexible or rigid proctoscopy. Patients 
undergoing TNT underwent clinical office exam at midtreatment and then at completion of treatment 
to gauge tumor response. Patients underwent restaging with CT and rectal MRI following completion 
of neoadjuvant therapy and before surgery.  
 
When a clinical complete response (cCR) was observed on examination, the possibility of pathologic 
complete response (pCR) was discussed with patients. cCR was defined as absence of viable tumor 
on digital examination, proctoscopy, and rectal MRI at 8 weeks after completion of radiotherapy [8]. 
Proctoscopic and digital assessment for sustained cCR was typically based on previously described 
criteria [8-10] (flat white scar or telangiectasia with absence of mucosal ulceration or nodularity). In 
borderline cases, discussion at the multidisciplinary meeting reached consensus agreement. Patients 
with cCR who deferred surgery and elected nonoperative management underwent close surveillance 
for local regrowth, including digital and proctoscopic exam along with MRI every 3-6 months, as 
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previously described [8]. The decision on whether to operate was generally made by 12-16 weeks 
following neoadjuvant therapy.  
All patients who received neoadjuvant therapy had a minimum follow-up of 12 months after 
completion of treatment. For analysis, the pCR rate and sustained cCR rate at 12 months were 
grouped together to determine the overall CR rate.    
 
Surgery 
Radical surgery was performed by MSK colorectal surgeons in accordance with the principles of 
anatomic total mesorectal excision using either the open (direct visualization) or the MIS 
(laparoscopic or robotic) approach. Temporary diverting ileostomies were created and closed at the 
surgeon’s discretion. Operations performed more than 12 months after completion of neoadjuvant 
therapy were excluded from analyses. 
 
Pathology 
Resection specimens were processed and evaluated in accordance with standard protocols.[11] The 
circumferential resection margin (CRM) and distal resection margin were considered involved if the 
tumor was <1 mm from the resection margin. pCR was defined as absence of viable tumor cells in 
the resection specimen after neoadjuvant therapy. Treatment responses in tumor specimens were 
graded as percent regression and for analysis were grouped as follows: 0, no tumor regression; 1, 
<25% regression; 2, 25% to 50% regression; 3, >50% regression; 4, 100% regression (pCR) [12].  
 
Recurrence and Statistical Analysis 
Distant-recurrence-free survival was calculated from completion of neoadjuvant therapy, and patients 
were censored at the date of last follow-up or the date of detection of local recurrence. Patients with 
residual disease after neoadjuvant therapy who declined further treatment were excluded from 
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survival analyses. The date of any recurrence was defined as the date of initial radiographic 
assessment indicating a likely recurrence with or without biopsy. Pelvic recurrences were categorized 
as local, and recurrences at other sites were categorized as distant. Mucosal regrowth after sustained 
cCR was considered a local recurrence, and patients with mucosal regrowth were therefore evaluated 
for distant recurrence. Recurrence-free survival events were defined as recurrence or death of any 
cause, while patients who were alive and free of recurrence were censored. 
 
Standard thresholds were used to group clinical and pathological data. Data are presented as medians 
with interquartile ranges unless otherwise stated. Groups were compared using the chi-square test for 
trend (categorical data) or the Kruskal-Wallis test (continuous data). Statistical analyses were 
performed using SPSS software (IBM). 
 
Results 
Of the 798 LARC patients included in the study, 67 patients were evaluated between June 1 and 
December 31, 2009; 135 patients in calendar year 2010; 98 in 2011; 110 in 2012; 145 in 2013; 179 in 
2014; and 64 between January 1 and March 1, 2015.  For analysis, the 202 patients evaluated 
between June 1, 2009, and December 31, 2010, were grouped together. The 243 patients evaluated 
between January 1, 2014, and March 1, 2015, were grouped together as well. Clinicopathologic 
characteristics were evaluated for all patients, and trends were evaluated over time in the five cohorts 
based on year of treatment. Baseline clinical characteristics and treatments are listed in Table 1.  
 
Rectal MRI was obtained in 84% of patients, while ERUS was the sole rectal staging modality in 
16%. Most tumors were clinically staged cT3 (84%) and cN+ (78%). The use of MRI increased from 
57% of patients in 2009-2010 to 98% in 2014-2015 (p < 0.001) (Figure 1). The proportion of 
pretreatment cN+ staged tumors increased from 72% in 2009-2010 to 83% in 2014-2015 (p = 0.001).  
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Prescribed neoadjuvant therapies were as follows: TNT in 51% of patients, chemoRT with planned 
adjuvant chemotherapy in 40%, and chemotherapy alone in 9%. Postoperative chemotherapy was 
administered in 73% of the chemoRT with planned adjuvant chemotherapy cohort and 37% of the 
total (Table 1). The use of chemoRT with planned adjuvant chemotherapy fell from 77% in 2009-
2010 to 16% in 2014-2015, while TNT increased from 17% to 76% during that period (p < 0.001 for 
both comparisons; Figure 1).  
 
Eighty-two percent of all patients underwent radical rectal resection within 12 months of completing 
neoadjuvant therapy. The proportion of patients managed nonoperatively (watch and wait) who 
completed at least 12 months of follow-up without requiring radical surgery increased from 10% in 
2009-2010 to 22% in 2014-2015 (p < 0.001; Table 1).  
 
Surgery details and perioperative outcomes for patients who underwent resection within 12 months 
of completing neoadjuvant therapy (n = 657) are listed in Table 2. The time to surgery increased over 
the study period, and the proportion of patients who underwent surgery more than 8 weeks after 
neoadjuvant therapy rose from 41% in 2009-2010 to 65% in 2014-2015 (p < 0.001). Among patients 
who were treated with chemoRT and planned adjuvant chemotherapy, the proportion of those who 
underwent surgery more than 8 weeks following chemoRT increased from 42% in 2009-2010 to 69% 
in 2014-2015 (p < 0.05).  
 
The proportion of cases treated with MIS increased from 33% in 2009-2010 to 70% in 2014-2015 (p 
< 0.001) (Figure 1). In 2014-2015, 98% of MIS operations were robot assisted. Ileostomy rates were 
unchanged, but ileostomy closure within 15 weeks of low anterior resection rose from 8% in 2009-
2010 to 75% in 2014-2015 (p < 0.001). Length of stay fell over time (p < 0.001), with the proportion 
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of patients staying 5 days or less increasing from 21% to 53% (p < 0.001). Clavien-Dindo grade III-
V complications decreased from 13% in 2009-2010 to 7% in 2014-2015 (p = 0.020), SSIs decreased 
from 24% to 8% (p < 0.001), and anastomotic leak after low anterior resection decreased from 11% 
to 3% (p = 0.011) (Table 2). 
 
Short-term oncologic outcomes and pathologic characteristics are listed in Table 3. The rate of CR 
(pCR or sustained cCR at 12 months) rose from 26% in 2009-2010 to 34% in 2014-2015 (p = 0.029) 
(Table 3). This was primarily due to an increase in cCRs from 10% to 21% (p < 0.001). The median 
number of lymph nodes in resected specimens increased from 14 in 2009-2010 to 19 in 2014-2015 (p 
< 0.001). The rate of clear CRM increased from 91% in 2009-2010 to 96% in 2014-2015 (p = 
0.046).   
 
Discussion 
We found several major changes in clinical and surgical management of LARC at MSK between 
2009 and 2015. There was a marked increase in utilization of TNT and a clear shift toward MRI as 
the pretreatment staging modality. Concurrent with the adoption of TNT we observed a rise in rates 
of TNM downstaging and complete response (defined by either pCR or sustained cCR at 12 months) 
and a lowering of the rate of involved CRM at surgery during the study period. There was a shift 
toward MIS and robotic surgery performed later, more than 8 weeks after completion of neoadjuvant 
therapy. In addition, the proportion of patients choosing nonoperative management steadily increased 
over the study period. As these changes in clinical management were implemented, we also found 
improvements in perioperative outcomes: fewer grade III-V complications, SSIs, and anastomotic 
leaks as well as shorter postoperative lengths of stay. The temporal changes in clinical practice and 
associated short-term outcome do not prove causality. Nonetheless, we believe these data add to the 
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existing rationale for extended neoadjuvant regimens in LARC and the use of minimally invasive and 
robotic surgery. 
 
The use of TNT, which combines induction or consolidation chemotherapy in addition to chemoRT 
before surgery, is a therapeutic option in NCCN guidelines [7] and represents a major change in 
LARC management at MSK. Previous reports from MSK have demonstrated higher rates of pCR and 
sustained cCR with adoption of TNT as well as a high level of treatment tolerance [13, 14].  
 
Outside the United States, TNT is still considered experimental. The recent Spanish GCR-3 phase II 
randomized trial found that the main benefit of induction chemotherapy prior to chemoRT was 
improved delivery of systemic chemotherapy and lower chemotherapy-related toxicity compared 
with postoperative adjuvant therapy; the rates of complete response were comparable to those for 
chemoRT alone. The Stockholm III trial reported higher rates of pCR with short-course radiotherapy 
and delayed surgery versus immediate surgery [15], and the addition of consolidative FOLFOX 
following short-course radiotherapy has been reported to result in a pCR rate of 17% [16]. The results 
of the RAPIDO trial on short-course radiotherapy followed by neoadjuvant chemotherapy are keenly 
anticipated [17]. In addition, TNT-based strategies are central to the NRG-GI002 phase II clinical 
trial, which has recently commenced recruitment [18]. 
 
The results of our study indicate that the TNT approach does not compromise surgical or 
perioperative outcomes and likely contributed to ongoing improvements in rectal cancer care. The 
optimal timing of preoperative chemotherapy, either before (induction) or after (consolidation) 
chemoRT has not been determined, and this question is subject to an ongoing prospective evaluation 
[8]. In previous reports [19, 20], long-term survival was not associated with pretreatment stage but 
was associated with response to therapy and posttreatment stage. Therefore, it may be anticipated that 
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optimization of the neoadjuvant approach using strategies such as TNT to maximize treatment 
response may translate into improved long-term outcomes.  
 
The time to surgery after completion of neoadjuvant therapy has increased, and by 2014-2015, 62% 
of patients underwent surgery more than 8 weeks after neoadjuvant therapy. In the chemoRT with 
planned adjuvant chemotherapy group, 72% of patients underwent surgery more than 8 weeks after 
completion of neoadjuvant therapy in 2014-2015. It is increasingly clear that responses to 
neoadjuvant therapy continue for at least 12 weeks from chemoRT, providing a rationale for delaying 
surgery beyond 8 weeks [21-23]. Interestingly, a recent French trial evaluating short-term outcomes 
after surgery at 7 versus 11 weeks post-completion of neoadjuvant treatment reported increased 
postoperative morbidity in the 11-week cohort (32% versus 45%), with no difference in pCR rates 
[24]. The difference in morbidity was primarily the result of increased medical complications (e.g., 
urinary and respiratory complications) in the 11-week group, with no increase in the anastomotic leak 
rate or reintervention/reoperation rate. Similarly to other recent reports [25, 26], we did not observe 
such findings in our study when surgery was performed beyond 12 weeks, and we did not note a 
compromise in short-term surgical outcome.  
The shift from ERUS to MRI seems to have resulted in a higher proportion of stage III (lymph node 
positive) disease diagnoses. Although both MRI and ERUS tend to be associated with overcalling of 
regional lymph nodes, MRI does allow discrimination by size and morphology, improving accuracy 
[27, 28],  MRI evaluates the entire pelvis, including proximal mesorectal, lateral pelvic sidewall, and 
inferior mesenteric nodes and also accurately delineates T3/4 disease, involvement of adjacent 
structures, and CRM status. MRI is also capable of quantifying response to neoadjuvant therapy, and 
there is an emerging role for diffusion-weighted MRI [29], increasingly pertinent to management 
after apparent cCR. The observed decrease in CRM positivity in resected specimens in our series is 
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likely multifactorial, but improved post-treatment MRI imaging undoubtedly assists surgical 
planning. 
 
Over the past two decades, widespread adoption of MIS has taken place in colorectal cancer 
management. The ROLARR trial [30] recently reported excellent results for robotic surgery 
performed by surgeons with varying experience of robotic surgery, with low rates of conversion to 
open surgery and low CRM positivity, similar to those for laparoscopic surgery.  
 
Data from multicenter randomized trials demonstrate clear benefits of MIS for colon cancer, with 
improved short-term outcomes without oncologic compromise [31]. Although MIS for rectal cancer 
surgery is now widespread, debate remains over the oncologic safety of the approach, driven by 
results from randomized controlled trials that call into question the oncologic adequacy of the 
laparoscopic total mesorectal excision specimen [32-35]. However, two large multicenter randomized 
controlled trials [4, 36] reported oncologic equivalency. Clearly, careful patient selection is important 
in determining which approach is optimal [37]. Unlike laparoscopic surgery, a robotic approach has 
been adopted by all surgeons at MSK, which speaks to the benefit perceived by surgeons [38].  We 
believe that improved visualization, better exposure, easier tissue dissection with wristed 
instrumentation, and enhanced stapling technology address many of the shortcomings of laparoscopic 
rectal surgery.  
 
There is increasing evidence that patients with cCR after neoadjuvant therapy can be managed 
expectantly, avoiding immediate surgery with potential for rectal preservation [9, 10, 39, 40]. The 
nonoperative approach requires strict follow-up to identify recurrence without oncologic compromise 
[9, 10, 39, 40]. With TNT, we have observed increasing numbers of patients with early cCR going 
beyond 6 months without radical resection [8]. Local regrowth is anticipated in 20–30% of patients 
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who undergo nonoperative management, necessitating salvage treatment usually within 12 months 
[39-43].  
 
Because our study was retrospective, these results are limited by potential unrecognized biases 
defining treatment allocation and outcomes throughout the period studied. Determining possible 
causative links between changes in management and clinical outcomes is not possible due to the 
retrospective nature of the study, and as a result we sought only to detail these changes. The observed 
improvements in short-term outcomes may also reflect changes in case selection or treatment 
guidelines. In addition, results from a high-volume comprehensive cancer center may not be directly 
translatable to other populations or health care systems.  
 
One criticism of the TNT approach is that it does not allow for adaptive treatment strategies based on 
individual clinical staging and could lead to potential overtreatment, particularly for stage II disease. 
Nonetheless, we believe it is important to document and analyze the considerable recent changes in 
rectal cancer management, which may influence short-term outcomes. It is reassuring that despite the 
multitude of changes to clinical practice, we do appear to see a consistent improvement in short-term 
outcomes during the treatment period. 
 
In conclusion, over the past decade, we have seen an evolution in the surgical management of LARC 
at MSK, against a background of increasing use of pre-operative MRI staging and adoption of the 
TNT approach, in which chemotherapy and chemoRT are delivered preoperatively. Over the same 
period, we observed increased rates of tumor downsizing, now seen in the majority of patients. Rectal 
resection is now most commonly performed 8 to 12 weeks after neoadjuvant therapy. Adoption of 
MIS with robotic rectal resection, enhanced recovery protocols, and SSI reduction strategies, may 
have contributed to the observed reductions in perioperative morbidity rates and the average length of 
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hospital stay. Increasingly, patients are expressing a strong preference for a nonoperative, watch-and- 
wait approach, which in our experience is facilitated by TNT. Continued observational studies, 
including registries, are required to monitor results and optimize care of LARC patients. 
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Figure 1. Trends in Management of LARC at MSK between June 2009 and March 2015. (A) 
The use of MRI and ERUS as the primary pretreatment staging modality at MSK between 2009 and 
2015 (n = 676). (B) Neoadjuvant treatment for LARC between 2009-2015 at MSK (n = 798). (C) 
Operative approach for surgical management of LARC between 2009 and 2015 at MSK (n = 657). 
(D) Rates of postoperative complications after surgery for LARC between 2009 and 2015 at MSK (n 
= 657). 
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Table 1. Clinical and Treatment Characteristics  
 
Characteristic 
No. (%) of Patients  
P†  Total* 
(n = 798)  
2009-2010 
(n = 202)  
2011 
(n = 98) 
2012 
(n = 110)  
2013 
(n = 145)  
2014-2015 
(n = 243)  
Age (years)        0.290 
   <55 
    55-75                  
     >75                 
359 (45) 
358 (45) 
  81 (10) 
79 (39) 
99 (49) 
24 (12) 
49 (50) 
41 (42) 
8 (8) 
55 (50) 
45 (41) 
10 (9) 
66 (46) 
60 (41) 
19 (13) 
110 (45) 
113 (47) 
20 (8) 
 
 
 
        
Sex          0.330 
    Female 
    Male 
327 (41) 
471 (59) 
80 (40) 
122 (60) 
34 (35) 
64 (65) 
43 (39) 
67 (61) 
58 (40) 
87 (60) 
112 (46) 
131 (54) 
 
 
        
Tumor height (cm) above anal verge 
   <5 
   5-10 
   >10 
 
264 (33) 
384 (48) 
150 (19) 
 
  57 (28) 
115 (57) 
  30 (15) 
 
34 (35) 
46 (47) 
18 (18) 
 
36 (33) 
56 (51) 
18 (16) 
 
51 (35) 
60 (41) 
34 (23) 
 
86 (35) 
107 (44) 
50 (21) 
0.986 
 
 
 
        
Pretreatment staging modality‡  
   ERUS  
   MRI  
   ERUS and MRI 
 
348 (51) 
568 (84) 
238 (35) 
 
120 (76) 
  90 (57) 
  53 (34) 
 
47 (64) 
65 (88) 
38 (51) 
 
68 (73) 
72 (77) 
47 (51) 
 
  67 (51) 
124 (94) 
  59 (45) 
 
46 (21) 
217 (98) 
  41 (19) 
 
<0.001 
<0.001 
<0.001 
        
cT stage              0.203 
   cT1/2 
   cT3 
   cT4 
54 (7) 
670 (84) 
74 (9) 
      16 (8) 
171 (85) 
15 (7) 
5 (5) 
81 (83) 
12 (12) 
6 (6) 
97 (88) 
7 (6) 
 14 (10) 
122 (84) 
  9 (6) 
13 (5) 
199 (82) 
  31 (13) 
 
 
 
        
cN stage             0.001 
   cN0 
   cN+ 
174 (22) 
624 (78) 
  57 (28) 
145 (72) 
27 (28) 
71 (73) 
24 (23) 
86 (78) 
24 (17) 
121 (83) 
 42 (17) 
201 (83) 
 
 
        
Neoadjuvant therapy       <0.001 
   ChemoRT with adjuvant chemo 
   Chemo alone§ 
   TNT 
320 (40) 
68 (9) 
410 (51) 
155 (77) 
12 (6) 
  35 (17) 
62 (63) 
4 (4) 
32 (33) 
43 (39) 
    10 (9) 
 57 (52) 
 22 (15) 
 21 (15) 
102 (70) 
38 (16) 
21 (9) 
184 (76) 
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Radical resection within 12 months 
after neoadjuvant therapy  
   No# 
   Yes 
 
 
141 (18) 
657 (82) 
 
   
21 (10) 
181 (90) 
 
 
10 (10) 
88 (90) 
 
 
21 (19) 
89 (81) 
 
  
36 (25) 
109 (75) 
 
 
  53 (22) 
190 (78) 
<0.001 
 
 
        
Postoperative chemotherapy (after 
resection within 12 months) 
 
n=657 
 
n=181 
 
n=88 
 
n=89 
 
n=109 
 
n=190 
<0.001 
   No 
   Yes 
 
360 (55) 
297 (45) 
  40 (22) 
141 (78) 
34 (39) 
54 (61) 
53 (60) 
36 (40) 
79 (72) 
30 (28) 
154 (81) 
  36 (19) 
 
 
Postoperative CT (in patients 
receiving chemoRT with 
adjuvant chemo) 
   No 
   Yes 
n=320 
 
 
86 (27) 
234 (73) 
n=155 
 
 
30 (19) 
125 (81) 
n=62 
 
 
15 (24) 
47 (76) 
n=43 
 
 
14 (33) 
29 (67) 
n=22 
 
 
8 (36) 
14 (34) 
n=38 
 
 
19 (50) 
19 (50) 
    0.002 
Abbreviations: ERUS, endorectal ultrasound; MRI, magnetic resonance imaging; TNT, total neoadjuvant therapy. 
*Patients who underwent initial assessment at Memorial Sloan Kettering between June 1, 2009, and March 1, 2015. 
†Chi-square test for trend.  
‡At Memorial Sloan Kettering. For 120 patients, preoperative staging was performed at other facilities.  
§The strategy of chemotherapy alone was employed as part of a split regimen of pre- and postoperative chemotherapy or as neoadjuvant treatment in patients who had 
previously received pelvic irradiation for another malignancy (e.g., cervix or prostate). It was also employed in patients who proceeded directly to surgery after an excellent 
response to induction chemotherapy and patients who declined radiotherapy (e.g., younger patients who wanted to preserve their fertility). 
#Patients who did not undergo resection due to nonoperative management after cCR or due to other medical reasons.  
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Table 2. Treatment Characteristics for Patients Undergoing Resection within 12 Months after Completion of Neoadjuvant Therapy  
 
Characteristic 
No. (%) of Patients 
P† Total* 
(n = 657) 
2009-2010 
(n = 181)  
2011 
(n = 88) 
2012 
(n = 89) 
2013 
(n = 109)  
2014-2015 
(n = 190)  
Time to surgery after NT (weeks) 
   <8  
   8-12  
   12-26 
   26-52 
 
317 (48) 
228 (35) 
  91 (14) 
21 (3) 
 
106 (59) 
  54 (30) 
  17 (9) 
4 (2) 
 
54 (61) 
23 (26) 
11 (13) 
0 (0) 
 
38 (43) 
35 (40) 
14 (16) 
2 (2) 
 
52 (48) 
42 (39) 
13 (12) 
2 (2) 
 
67 (35) 
74 (39) 
36 (19) 
13 (7) 
<0.001 
 
 
 
        
Restorative procedure             0.696 
   Yes 
   No‡   
502 (76) 
155 (24) 
141 (78) 
   40 (22) 
66 (75) 
22 (25) 
70 (78) 
19 (22) 
83 (76) 
28 (24) 
142 (75) 
48 (25) 
 
 
        
Surgical approach                   <0.001 
   Open 
   MIS 
278 (42)  
379 (58)  
121 (67) 
  60 (33) 
48 (54) 
40 (46) 
19 (22) 
70 (78) 
33 (30) 
76 (70) 
57 (30) 
133 (70) 
 
 
        
MIS type       <0.001 
   Laparoscopic  
   Robotic  
  70 (18) 
309 (82) 
31 (52) 
29 (48) 
19 (47) 
21 (53) 
14 (20) 
56 (80) 
3 (4) 
73 (96) 
3 (2) 
130 (98) 
 
 
        
Median hospital stay, days (IQR) 6.0 (4.5-7.5) 7.0 (6-8) 7.0 (5-9) 6.0 (4-8) 6.0 (4.5-7.5) 5.0 (3.5-6.5)    <0.001 
        
Length of hospital stay           <0.001 
   <5 days 
   >5 days 
248 (38) 
409 (62) 
37 (21) 
144 (79) 
22 (25) 
66 (75) 
32 (36) 
57 (64) 
55 (50) 
54 (50) 
102 (53) 
  88 (47) 
 
 
        
Diverting ileostomy§                   
   No 
   Yes 
n = 502 
  79 (16) 
423 (84) 
n = 141 
  23 (16) 
118 (84) 
n = 66 
 9 (14) 
57 (86) 
n = 70 
12 (17) 
58 (83) 
n = 83  
13 (16) 
70 (84) 
n = 142 
  22 (16) 
120 (84) 
0.985 
 
 
        
Ileostomy closure within 15 weeks          
   No 
   Yes 
n = 423 
259 (61) 
164 (39) 
n = 118 
109 (92) 
   9 (8) 
n = 57 
48 (84) 
  9 (16) 
n = 58 
38 (66) 
20 (34) 
n = 70 
32 (46) 
38 (54) 
n = 120 
32 (27) 
88 (73) 
<0.001 
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Postoperative complications within 30 days        
   Grade III-V complications        0.020 
      No  
      Yes 
590 (90) 
  67 (10) 
157 (87) 
  24 (13) 
77 (89) 
11 (11) 
74 (86) 
12 (14) 
103 (94) 
  6 (6) 
176 (93) 
14 (7) 
 
 
        
   Surgical site infection        <0.001 
      No  
      Yes 
553 (84) 
106 (16) 
137 (76) 
44 (24) 
66 (75) 
22 (25) 
75 (84) 
14 (16) 
  98 (90) 
11 (10) 
175 (92) 
15 (8) 
 
 
        
   Anastomotic leak (grade III) §  
      No 
      Yes 
n = 502 
463 (92) 
39 (8) 
n = 141  
126 (89) 
  15 (11) 
n = 66 
61 (92) 
5 (8) 
n = 70  
59 (84) 
11 (16) 
n = 83 
79 (95) 
4 (5) 
n = 142 
138 (97) 
  4 (3) 
0.008 
 
 
Abbreviations: NT, neoadjuvant therapy; MIS, minimally invasive surgery; IQR, interquartile range. 
*Patients who underwent initial assessment at Memorial Sloan Kettering between June 1, 2009, and March 1, 2015. 
†Chi-square test for trend. 
‡Abdominoperineal resection or rectal resections with a permanent colostomy (e.g., low Hartmann’s procedure). 
§After a low anterior resection.  
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Table 3. Short-Term Oncological Outcomes and Pathologic Characteristics for Entire Cohort 
 
Outcome or characteristic 
No. (%) of Patients  
P†  Total* 
 
2009-2010 
 
2011 
 
2012 
  
2013 
 
2014-2015 
  
Outcomes n = 798 n = 202 n = 98 n = 110 n = 145 n = 243  
  Complete response 12 months after NT       
      No 
      Yes‡ 
 
551 (69) 
247 (31) 
 
149 (74) 
   53 (26) 
 
75 (76) 
23 (24) 
 
71 (65) 
39 (35) 
 
95 (66) 
50 (34) 
 
161 (66) 
   82 (34) 
0.029 
 
 
        
  cCR 12 months after NT 135 (17) 21 (10) 10 (10) 20 (18) 32 (22) 52 (21) <0.001 
        
   Downstaging after NT           
      T downstaging       0.724 
         No 
         Yes 
256 (32) 
542 (68) 
68 (34) 
134 (66) 
37 (38) 
61 (62) 
28 (25) 
82 (75) 
  39 (27) 
106 (73) 
  84 (35) 
159 (65) 
 
 
        
      N downstaging       0.019 
         No 
         Yes 
327 (41) 
471 (59) 
93 (46) 
109 (54) 
44 (45) 
54 (55) 
49 (44) 
61 (56) 
51 (35) 
94 (65) 
  90 (37) 
153 (63) 
 
 
        
      TNM downstaging       0.002 
         No 
         Yes 
242 (30) 
556 (70) 
77 (38) 
125 (62) 
31 (32) 
67 (68) 
36 (33) 
74 (67) 
  35 (24) 
110 (76) 
  63 (26) 
180 (74) 
 
 
        
        
Pathology results n = 657  n = 181 n = 88 n = 89  n = 109 n = 190   
   pCR in specimen                                                          
      No 
      Yes 
 
545 (83) 
112 (17) 
 
149 (82) 
32 (18) 
 
75 (85) 
13 (15) 
 
70 (79) 
19 (21) 
 
91 (83) 
18 (17) 
 
160 (84) 
 30 (16) 
0.715 
 
 
        
   >95% response in specimen§                        
      No   
      Yes                                                                         
n = 642 
429 (67) 
213 (33) 
n = 176 
123 (70) 
  53 (30) 
n = 82 
51 (62) 
31 (38) 
n = 88 
58 (66) 
30 (34) 
n = 107 
73 (68) 
34 (32) 
n = 189 
124 (66) 
   65 (34) 
0.598 
 
 
        
   Tumor regression (Rodel scale)              0.001 
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Abbreviations: NT, neoadjuvant therapy; cCR, clinical complete response; pCR, pathologic complete response; LN, lymph nodes; IQR, interquartile range; CRM, 
circumferential resection margin; MIS, minimally invasive surgery; DRM, distal resection margin.  
*Patients who underwent initial assessment at Memorial Sloan Kettering between June 1, 2009, and March 1, 2015. 
†Chi-square test for trend. 
‡Surgical patients with pCR and nonsurgical patients with cCR at 12 months.  
§Including pCR. Data were available for 642 of the 657 surgery patients. 
#<1 mm.                                                        
 
 
 
      0/1 (0 to <25%) 
      2 (25 to 50%)  
      3 (>50%) 
      4 (100%) 
  63 (10) 
119 (19) 
349 (54) 
111 (17) 
4 (2) 
  40 (23) 
 100 (57) 
  32 (18) 
6 (87) 
  11 (13) 
52 (63) 
13 (16) 
7 (7) 
18 (21) 
45 (51) 
18 (21) 
11 (10) 
19 (18) 
59 (55) 
18 (17) 
35 (19) 
31 (16) 
93 (49) 
30 (16) 
 
 
 
 
        
   No. of LN resected, median (IQR) 16 (12.5-20.5) 14 (11-117) 15 (12-18) 15 (12.5-18.5) 20 (14.5-25.5) 19 (13.5-24.5) <0.001 
        
   Negative CRM#         
      All surgeries (n = 657) 617 (94.1) 165 (91) 82 (93) 85 (96) 104 (95) 182 (96) 0.046 
      Open surgery (n = 278) 
      MIS (n = 379) 
245 (91.0) 
364 (96.3) 
109 (90) 
  56 (93) 
45 (94) 
37 (93) 
16 (84) 
69 (99) 
30 (91) 
74 (97) 
 53 (93) 
129 (97) 
0.683 
0.148 
        
   Negative DRM#         
      All surgeries (n = 657) 645 (98.2)     179 (99) 85 (97) 84 (94) 109 (100) 188 (99) 0.499 
      Open surgery (n = 278) 
      MIS (n = 379) 
     276 (99) 
369 (97.0) 
  121 (100) 
 58 (97) 
47 (98) 
38 (95) 
  19 (100) 
64 (93) 
 33 (100) 
 76 (100) 
  56 (98) 
 132 (99) 
0.415 
0.053 
